A Phase 2 interventional study of Ascorbic acid and Normal Saline in Lung Cancer, sponsored by The Canadian College of Naturopathic Medicine. Terminated at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-14.
Sponsored by The Canadian College of Naturopathic Medicine · Phase 2, Interventional, and Supportive care
Insufficient recruitment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 383 studies in Lung Neoplasms with a site in Canada — 66 open to participants now, 99 under way, 26 of them phase 3. Lung Neoplasms · Canada.
Among the 383 studies in Lung Neoplasms with a site in Canada, this one is the 306th largest by enrollment of the 315 interventional ones that give a count, is one of 12 that started in 2024, is one of 77 in phase 2, and was the 332nd registered.
5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.
Browse Lung Neoplasms studies →66 of the 383 studies in Lung Neoplasms with a site in Canada are open now. Recruiting first, the newest first:
Centre hospitalier de l'Université de Montréal (CHUM) · Sites in Canada
Ages 18+
SystImmune Inc. · Sites in Canada, United States, Australia and 13 more countries
Ages 18+
Bristol-Myers Squibb · Sites in Canada, United States, Belgium and 10 more countries
Ages 18+
University of British Columbia · Sites in Canada
Ages 19–80 · Healthy volunteers
University Health Network, Toronto · Sites in Canada
Ages 18+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
383 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 77 · Phase 2 117 · Phase 3 86 · Phase 4 4
First in 1994; this study’s year is marked. 12 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 3 is below the median of 60 across 3,668 interventional studies indexed under Lung Neoplasms.
Median enrollment 100 across the 315 interventional studies, 137 across the 56 observational. Of the 253 that completed or were terminated, 64 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
139 of 383 have an industry lead sponsor. The 10 most frequent:
The Canadian College of Naturopathic Medicine is the lead sponsor of 19 studies on the registry; 1 is open to participants now.
The Canadian College of Naturopathic Medicine has 3 studies filed under Lung Neoplasms — fewer than ten, so there is no comparison to draw.
29 of the studies in Lung Neoplasms with a site in Canada that are under way reach primary completion within a year, 7 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04093167Phase 3Canadian Cancer Trials GroupStudy of CTDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer | 2026-12-31 |
| NCT04380636Phase 3Merck Sharp & Dohme LLCStudy of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012) | 2027-05-05 |
| NCT05920356Phase 3AmgenA Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202) | 2027-06-30 |
| NCT06635824Phase 3GenmabTrial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06) | 2027-07-30 |
| NCT03793179Phase 3National Cancer Institute (NCI)Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer | 2027-09-30 |
Add all 29 to your calendar (.ics) → With an account.
Among the 383 studies in Lung Neoplasms with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a two arm RCT evaluating the effect of intravenous vitamin C versus placebo in patients with incurable non-small cell lung cancer. Participants in both arms will be receiving platinum doublet chemotherapy with or without concurrent immunotherapy as standard care. We plan to enroll 90 patients over 5 years.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1g/kg IVC administered twice weekly for 6 months.
Drug: Ascorbic acid
Equivalent volume normal saline administered twice weekly for 6 months.
Other: Normal Saline
High dose ascorbic acid delivered intravenously
Also known as: Vitamin C
0.9% NaCl solution
Also known as: Sodium Chloride Solution
Change in Quality of Life
Participant reported quality of life (QOL) measured using the Functional Assessment of Cancer Therapy - Lung (FACT-L). FACT-L is a validated tool for assessing QOL in patients with lung cancer. FACT scores are normalized to values between 0-100, where 0 is the worst QOL and 100 is the best QOL imaginable. Each chemotherapy cycle is 3 weeks in length.
Time frame: Baseline, Chemo cycles 1-4, 6 months, 12 months
Chemotherapy-Related Toxicities
Frequency of adverse events (AE) which are commonly experienced by patients undergoing chemotherapy. Measured using the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). 31 symptoms were selected by the investigators.
Time frame: 12 months
Frequency of Discontinuation of Chemotherapy
Patients often discontinue chemotherapy due to side effects. The investigators will monitor the incidence of stopping chemotherapy and compare the number of patients who stop chemotherapy in both arms.
Time frame: 6 months
Change in General Symptom Burden
Measured using the Edmonton Symptom Assessment Scale, which measures 9 symptoms commonly experienced by cancer patients. Each symptom is rated on a scale of 0-10, where 0 is the best symptom and 10 is the worst symptom. Each chemotherapy cycle is 3 weeks in length.
Time frame: Baseline, chemo cycles 1-4, 6 months, 12 months
Change in C-Reactive Protein Levels
The investigators will monitor the changes in C-reactive protein (CRP), a common indicator of systemic inflammation. Mean changes in CRP will be compared between arms. Each chemotherapy cycle is 3 weeks in length.
Time frame: Baseline, chemo cycles 1-4, 6 months, 12 months
Tumour Progression
The investigators will monitor tumour progression using the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, which measures the incidence of complete response, partial response, stable disease, and progressive disease during treatments.
Time frame: 12 months
Survival
The incidence of all cause mortality will be compared between arms.
Time frame: 24 months
Safety
The investigators will monitor the incidence of all adverse events in both arms to add to the safety profile of IVC in this population.
Time frame: 6 months
Cytotoxicity
The investigators will assess the ability of IVC to bring serum ascorbate levels to at least 15mM, which is the hypothesized level at which cytotoxic effects may occur. Levels 15mM or above will be considered adequate.
Time frame: 12 months
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Individual participant data will not be shared with other researchers. Cumulative data not present in the manuscript or on this website may be shared upon request.
Ran from Oct 2024 to primary completion in Sep 2026, 23 months.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 14, 2026: primary completion Oct 2030 → Sep 2026 and completion Oct 2031 → Sep 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
Insufficient recruitment
Insufficient recruitment
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ascorbic Acid
The Canadian College of Naturopathic Medicine